Is ABBVIE financially healthy?

On 30 September 2026 ABBVIE held 10.77B USD in cash and short-term investments against total debt of 80.90B USD. Its current ratio is 0.87: what falls due within a year against what turns into cash within a year. Over the last twelve months it generated 19.76B USD of free cash flow.

ABBVIE's revenue grew 6.0% a year over its last five fiscal years, from 45.80B USD in fiscal year 2020 to 61.16B USD in fiscal year 2025. Over the last twelve months it was up 10.7% on the twelve months before.

Where can I find ABBVIE's annual report (10-K)?

ABBVIE files its annual report (Form 10-K) and its quarterly reports (Form 10-Q) with the US Securities and Exchange Commission, on its EDGAR site; the figures on these pages come from them.

ABBVIE
D
Quotes are delayed by 15 minutes

ABBV

Arincen ScoreBeta73/100

73/100B

294.86

USD

9.02

(3.16%)

Post Trading·295.20USD+0.34(+0.12%)

Last updated: 4 Nov, 19:57 GMT-5 · Delayed 15 min

Fair value398.80Plus-26%299Price 294.86499

Q4 FY2026 · Earnings report

EPS estimate 3.89Revenue estimate 18.33B

Q4 FY2026 · Earnings report

Wednesday 3 February

EPS estimate 3.89Revenue estimate 18.33B

Fair value398.80Plus-26%299Price 294.86499

Q4 FY2026 · Earnings report

EPS estimate 3.89Revenue estimate 18.33B

Q4 FY2026 · Earnings report

Wednesday 3 February

EPS estimate 3.89Revenue estimate 18.33B

Overview Financials Signals News Forecast Earnings Dividends Company

ABBVIE financials

Yes. ABBVIE earned 10.35B USD of net income over the last twelve months, 15.7% of its revenue. It made a profit in 17 of its 17 fiscal years since 2009.

Revenue (TTM): 66.01B USD
Net income (TTM): 10.35B USD
Free cash flow (TTM): 19.76B USD
Cash and short-term investments: 10.77B USD
Total debt: 80.90B USD
Shareholders' equity: 30.13B USD

Cash, debt and equity as of 30 Sept 2026.

ABBVIE earnings

Next earnings · Q4 FY2026

3 Feb 2027

EPS estimate

3.89 USD

Revenue estimate

18.33B USD

Last quarter · Q3 FY2026

EPS3.82Beat +2.4%Revenue17.40BBeat +0.5%

Revenue

ReportedEstimate

EPS

ReportedEstimate

Period	Report date	EPS estimate	Reported EPS	Surprise	EPS growth	Revenue estimate	Reported revenue	Surprise	Revenue growth
Q2 FY2028	—	4.51	—	—	—	19.67B	—	—	—
Q1 FY2028	—	4.04	—	—	+17.68%	18.58B	—	—	+12.55%
Q1 FY2027	—	3.43	—	—	+29.39%	16.51B	—	—	+10.05%
Q4 FY2026	3 Feb 2027	3.89	—	—	+43.54%	18.33B	—	—	+10.29%
Q3 FY2026	30 Oct 2026	3.73	3.82	+2.41%	+105.38%	17.32B	17.40B	+0.51%	+10.32%
Q2 FY2026	31 Jul 2026	3.61	3.65	+1.11%	+22.90%	16.80B	16.99B	+1.11%	+10.16%
Q1 FY2026	29 Apr 2026	2.59	2.65	+2.32%	+7.72%	14.72B	15.00B	+1.93%	+12.43%
Q4 FY2025	4 Feb 2026	2.65	2.71	+2.26%	+25.46%	16.41B	16.62B	+1.25%	+10.04%
Q3 FY2025	31 Oct 2025	1.77	1.86	+5.08%	-38.00%	15.59B	15.78B	+1.22%	+9.10%
Q2 FY2025	31 Jul 2025	2.88	2.97	+3.13%	+12.08%	15.03B	15.42B	+2.62%	+6.65%

Period	EPS estimate	Reported EPS	Surprise	EPS growth	Revenue estimate	Reported revenue	Surprise	Revenue growth
FY2028	18.00	—	—	+10.36%	79.40B	—	—	+7.78%
FY2027	16.31	—	—	+16.76%	73.67B	—	—	+8.87%
FY2026	13.97	—	—	+39.70%	67.67B	—	—	+10.64%
FY2025	9.94	10.00	+0.61%	-1.19%	60.97B	61.16B	+0.32%	+8.57%
FY2024	10.08	10.12	+0.37%	-8.91%	56.04B	56.33B	+0.52%	+3.71%
FY2023	11.13	11.11	-0.19%	-19.90%	54.05B	54.32B	+0.50%	-6.44%
FY2022	13.76	13.87	+0.77%	+9.21%	58.27B	58.05B	-0.37%	+3.30%

ABBVIE growth and profitability

Full income statement

Revenue (TTM): 66.01B USD
Net income (TTM): 10.35B USD
Gross margin: 76.25%
Operating margin: 35.53%
Net margin: 15.68%

Revenue / Net income

Revenue Net income Net margin

Period	Revenue	Growth	Net income	Growth	Gross margin	Operating margin	Net margin	EBITDA	Growth
FY2025	61.16B	+8.57%	4.23B	-1.22%	70.24%	32.85%	6.91%	17.63B	+18.24%
FY2024	56.33B	+3.71%	4.28B	-12.03%	69.99%	16.22%	7.59%	14.91B	-13.17%
FY2023	54.32B	-6.44%	4.86B	-58.91%	62.42%	23.49%	8.95%	17.17B	-28.97%
FY2022	58.05B	+3.30%	11.84B	+2.55%	70.00%	31.21%	20.39%	24.17B	+1.01%
FY2021	56.20B	+22.69%	11.54B	+150.04%	68.96%	31.89%	20.54%	23.93B	+94.21%

Period	Revenue	Net income	Gross margin	Operating margin	Net margin
Q3 FY2026	17.40B	4.22B	84.97%	37.25%	24.26%
Q2 FY2026	16.99B	3.61B	74.74%	37.86%	21.27%
Q1 FY2026	15.00B	699.00M	71.88%	31.56%	4.66%
Q4 FY2025	16.62B	1.82B	72.61%	34.96%	10.93%
Q3 FY2025	15.78B	186.00M	66.38%	12.07%	1.18%

How ABBVIE makes its money

Revenue61.16B 100.0%

Cost of revenue18.20B 29.8%

Gross profit42.96B 70.2%

Research and development9.10B 14.9%

Selling and administration14.01B 22.9%

Operating income20.09B 32.8%

Tax2.36B 3.9%

Other expense13.50B 22.1%

Net income4.23B 6.9%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

ABBVIE revenue breakdown

By product

FY2025

30.2%SKYRIZI14.3%RINVOQ7.8%H U M I R A6.5%Botox Therapeutic6.2%Vraylar4.9%Imbruvica4.8%VENCLEXTA4.5%Other Products4.5%Botox Cosmetic2.3%MAVYRET2.2%Ubrelvy2.2%Other Aesthetics1.8%Qulipta1.7%Other Eye Care1.7%Juvederm Collection1.6%Linzess/Constella0.8%Ozurdex0.7%Lumigan/Ganfort0.7%Duodopa0.4%Other Neuroscience0.3%Alphagan/Combigan

Segment	Revenue	Share of revenue	Change on the year
SKYRIZI	17.56B	30.2%	+49.9%
RINVOQ	8.30B	14.3%	+39.1%
H U M I R A	4.54B	7.8%	-49.5%
Botox Therapeutic	3.77B	6.5%	+14.8%
Vraylar	3.62B	6.2%	+10.8%
Imbruvica	2.87B	4.9%	-14.3%
VENCLEXTA	2.79B	4.8%	+8.1%
Other Products	2.63B	4.5%	-13.4%
Botox Cosmetic	2.60B	4.5%	-4.3%
MAVYRET	1.32B	2.3%	+0.5%
Ubrelvy	1.27B	2.2%	+26.3%
Other Aesthetics	1.27B	2.2%	-1.1%
Qulipta	1.04B	1.8%	+57.4%
Other Eye Care	1.01B	1.7%	+19.1%
Juvederm Collection	993.00M	1.7%	-15.6%
Linzess/Constella	907.00M	1.6%	-4.9%
Ozurdex	493.00M	0.8%	-0.2%
Lumigan/Ganfort	410.00M	0.7%	-4.4%
Duodopa	381.00M	0.7%	-14.8%
Other Neuroscience	207.00M	0.4%	-38.8%
Alphagan/Combigan	197.00M	0.3%	-20.6%

By region

FY2025

95.2%UNITED STATES4.8%Non-US

Region	Revenue	Share of revenue	Change on the year
UNITED STATES	46.60B	95.2%	+8.3%
Non-US	2.36B	4.8%	-82.2%

Operating and free cash flow

Full cash flow statement

Operating cash flow Free cash flow

Fiscal year	Operating cash flow	Free cash flow
FY2025	19.03B	17.82B
FY2024	18.81B	17.83B
FY2023	22.84B	22.06B
FY2022	24.94B	24.25B
FY2021	22.78B	21.99B
FY2020	17.59B	16.79B
FY2019	13.32B	12.77B
FY2018	13.43B	12.79B
FY2017	9.96B	9.43B
FY2016	7.04B	6.56B

ABBVIE financial health

Full balance sheet

Cash and short-term investments: 10.77B USD
Total debt: 80.90B USD
Net cash: -70.13B USD
Free cash flow (TTM): 19.76B USD
Current ratio: 0.87
Debt to equity: 2.69
Piotroski score: 8 / 9
Altman Z-score: 3.25

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow

Fiscal year	Cash and short-term investments	Total debt	Free cash flow
FY2025	5.26B	69.07B	17.82B
FY2024	5.56B	67.84B	17.83B
FY2023	12.82B	60.12B	22.06B
FY2022	9.23B	64.19B	24.25B
FY2021	9.83B	77.58B	21.99B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity

Fiscal year	Total assets	Total liabilities	Shareholders' equity
FY2025	133.96B	137.19B	-3.27B
FY2024	135.16B	131.80B	3.33B
FY2023	134.71B	124.31B	10.36B
FY2022	138.81B	121.52B	17.25B
FY2021	146.53B	131.09B	15.41B
FY2020	150.57B	137.47B	13.08B
FY2019	89.12B	97.29B	-8.17B
FY2018	59.35B	67.80B	-8.45B
FY2017	70.79B	65.69B	5.10B
FY2016	66.10B	61.46B	4.64B

ABBVIE valuation

Price to earnings ratio (TTM): 50.58
Forward P/E (FY2026): 21.11
Price to sales (TTM): 7.89
Price to book: 17.30
EV / EBITDA (TTM): 24.48

Capital structure

Market capitalization

521.05B USD

Total debt

80.90B USD

−

Cash and short-term investments

10.77B USD

Enterprise value

591.18B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate

Fiscal year	P/E	Forward P/E	P/S	P/B	EV/EBITDA
FY2028 (est.)	16.38	—	—	—	—
FY2027 (est.)	18.08	16.38	—	—	—
FY2026 (est.)	21.11	18.08	—	—	—
Now (TTM)	50.58	18.48	7.89	17.30	24.48
FY2025	96.41	16.36	6.63	-123.96	26.61
FY2024	74.04	17.89	5.58	94.54	25.26
FY2023	56.77	15.36	5.04	26.45	18.71
FY2022	24.30	14.51	4.93	16.59	14.11
FY2021	20.90	9.84	4.26	15.55	12.85

ABBVIE against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Johnson & Johnson, Merck & Co., Amgen, Gilead Sciences, Eli Lilly and, and Pfizer, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

P/E (today)Below its median50.6
18.9177.5
Gross marginHighest in 5 years70.2%
62.4%70.2%
Against its peers: 6 of 7Peers' median 73.2%
Operating marginHighest in 5 years32.8%
16.2%32.8%
Against its peers: 4 of 7Peers' median 32.6%
Net marginLowest in 5 years6.9%
6.9%20.5%
Against its peers: 7 of 7Peers' median 28.3%
Free cash flow marginLowest in 5 years29.1%
29.1%41.8%
Against its peers: 2 of 7Peers' median 20.0%
Revenue growthAbove its median8.6%
-6.4%22.7%
Against its peers: 3 of 7Peers' median 4.2%
EPS growthAt its median-0.8%
-59.0%137.1%
Against its peers: 6 of 7Peers' median 89.4%
Debt to EBITDAAbove its median3.92×
2.66×4.55×
Against its peers: 6 of 7Peers' median 1.81×
Current ratioBelow its median0.67
0.660.96
Against its peers: 7 of 7Peers' median 1.35

Figure	FY2025	5-year low – high	Against its history	Against its peers
P/E (today)	50.6	18.9177.5	Below its median	—
Gross margin	70.2%	62.4%70.2%	Highest in 5 years	6 of 7
Operating margin	32.8%	16.2%32.8%	Highest in 5 years	4 of 7
Net margin	6.9%	6.9%20.5%	Lowest in 5 years	7 of 7
Free cash flow margin	29.1%	29.1%41.8%	Lowest in 5 years	2 of 7
Revenue growth	8.6%	-6.4%22.7%	Above its median	3 of 7
EPS growth	-0.8%	-59.0%137.1%	At its median	6 of 7
Debt to EBITDA	3.92×	2.66×4.55×	Above its median	6 of 7
Current ratio	0.67	0.660.96	Below its median	7 of 7

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

ABBVIE dividends

Annual dividend: 7.28 USD
Dividend yield (indicated): 2.47%
Payout ratio: 149.91%
Years of dividend growth: 13
Frequency: Quarterly
Last payment: 1.82 USD
Last ex-dividend date: 15 Jan 2027
Last payment date: 16 Feb 2027

Dividends per share

Year	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Dividends per share	6.56	6.20	5.92	5.64	5.20	4.72	4.28	3.59	2.56	2.28

ABBVIE ownership

Institutions: 76.07%
Institutional holders: 4,353 (+130)
Free float: 99.82%

InstitutionsOthers

As of 30 Jun 2026

Insider trading

Quarter	Sales	Shares acquired	Shares disposed of
Q3 2026	1	32.90K	65.42K
Q2 2026	0	12.49K	0.00
Q1 2026	5	564.06K	209.10K
Q4 2025	0	249.00	0.00

Shares outstanding

Basic shares Diluted shares Change in diluted shares

Fiscal year	Basic shares	Diluted shares	Change in diluted shares
FY2025	1.77B	1.77B	+0.06%
FY2024	1.77B	1.77B	0.00%
FY2023	1.77B	1.77B	-0.28%
FY2022	1.77B	1.78B	+0.06%
FY2021	1.77B	1.78B	+6.22%

Common questions about ABBVIE's financials

Source: Financial Modeling Prep

ABBVIE
D
Quotes are delayed by 15 minutes

ABBV

ABBVIE financials

ABBVIE earnings

Revenue

EPS

ABBVIE growth and profitability

Revenue / Net income

How ABBVIE makes its money

ABBVIE revenue breakdown

By product

By region

Operating and free cash flow

ABBVIE financial health

Cash, debt and free cash flow

Assets, liabilities and equity

ABBVIE valuation

Capital structure

Valuation over time

ABBVIE against its own history

ABBVIE dividends

Dividends per share

ABBVIE ownership

Insider trading

Shares outstanding

Common questions about ABBVIE's financials

Is ABBVIE profitable?

Is ABBVIE financially healthy?

Is ABBVIE growing?

Where can I find ABBVIE's annual report (10-K)?

Need help?

ABBVIE DQuotes are delayed by 15 minutes

ABBV

ABBVIE financials

ABBVIE earnings

Revenue

EPS

ABBVIE growth and profitability

Revenue / Net income

How ABBVIE makes its money

ABBVIE revenue breakdown

By product

By region

Operating and free cash flow

ABBVIE financial health

Cash, debt and free cash flow

Assets, liabilities and equity

ABBVIE valuation

Capital structure

Valuation over time

ABBVIE against its own history

ABBVIE dividends

Dividends per share

ABBVIE ownership

Insider trading

Shares outstanding

Common questions about ABBVIE's financials

Is ABBVIE profitable?

Is ABBVIE financially healthy?

Is ABBVIE growing?

Where can I find ABBVIE's annual report (10-K)?

Need help?

ABBVIE
D
Quotes are delayed by 15 minutes